Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts give Savara a consensus rating of "Moderate Buy" from nine firms (1 sell, 1 hold, 6 buy, 1 strong buy) with an average 12‑month price target of $9.00.
• The stock is trading around $5.61 with a market cap of $1.15 billion and a one‑year range of $1.89–$7.01; Savara reported a quarterly EPS of ($0.13) (missing estimates) and carries a negative P/E while analysts forecast ~‑0.48 EPS for the year.
• Savara is a clinical‑stage biopharma focused on rare respiratory diseases and its lead candidate, Molgradex (GM‑CSF), is currently under regulatory review for autoimmune pulmonary alveolar proteinosis (PAP).

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $9.00.

A number of brokerages have commented on SVRA. Guggenheim reaffirmed a "buy" rating on shares of Savara in a report on Tuesday, December 23rd. Oppenheimer set a $10.00 target price on Savara in a report on Tuesday, December 23rd. Wall Street Zen lowered Savara from a "hold" rating to a "sell" rating in a report on Saturday, March 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a report on Thursday, January 22nd. Finally, William Blair set a $10.00 target price on Savara in a report on Monday, March 16th.

Savara Stock Performance

Shares of NASDAQ SVRA opened at $5.61 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 11.85. The stock's fifty day moving average price is $5.54 and its two-hundred day moving average price is $5.32. Savara has a one year low of $1.89 and a one year high of $7.01. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -10.58 and a beta of 0.32.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Friday, March 13th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). On average, equities analysts forecast that Savara will post -0.48 EPS for the current year.

Institutional Trading of Savara

Several large investors have recently modified their holdings of SVRA. Prudential Financial Inc. acquired a new stake in shares of Savara during the 2nd quarter worth $30,000. BNP Paribas Financial Markets grew its holdings in shares of Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock worth $31,000 after purchasing an additional 4,626 shares in the last quarter. Brevan Howard Capital Management LP acquired a new stake in shares of Savara during the 2nd quarter worth $33,000. Russell Investments Group Ltd. grew its holdings in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock worth $37,000 after purchasing an additional 9,463 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Savara during the 3rd quarter worth $44,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.